

No.	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for delay correspond to:
1	16/NE/0279	198051	TIDaL: Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)	Yes	24/04/2018	21/11/2017	05/04/2018	29/09/2016	05/12/2017	05/04/2018	19/04/2018	
2	17/EM/0361	234065	Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-	Yes	20/03/2018	20/09/2017	30/01/2018	11/01/2018	25/01/2018	01/02/2018	22/02/2018	
3	17/LO/1509	232288	A phase 3 randomised, double blind, clinical trial investigating the effectiveness of repurposed simvastatin compared to placebo, in secondary progressive multiple sclerosis, in slowing the progression of disability (MS-STAT2)	Yes	04/09/2018	15/05/2018	10/07/2018	19/01/2018	15/08/2018	21/08/2018	21/08/2018	
4	17/LO/1819	210698	BladderPath: Image Directed Redesign of Bladder Cancer Treatment Pathways	Yes	22/08/2018	30/01/2018	28/06/2018	04/12/2017	18/07/2018	17/07/2018	07/08/2018	
5	17/NE/0061	215780	COlchicine for preventioN of Vascular Inflammation in Non-CardioEmbolic stroke – a randomised clinical trial of low-dose colchicine for secondary prevention after stroke	Yes	23/05/2018	01/11/2017	05/04/2018	25/07/2017	03/05/2018	14/05/2018	15/05/2018	
6	17/NW/0529	226070	Packing of Perianal Abscess Cavities (PPAC)	Yes	14/05/2018	23/08/2017	17/04/2018	05/12/2017	23/02/2018	23/04/2018	24/04/2018	
7	17/SC/0142	215503	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension	Yes	21/03/2018	23/08/2017	17/01/2018	24/04/2017	12/02/2018	15/02/2018	12/03/2018	
8	17/SC/0391	227067	The High-volume Haemodiafiltration vs High-flux Haemodialysis Registry Trial – H4RT	Yes	20/07/2018	09/02/2018	03/07/2018	07/09/2017	08/05/2018	03/07/2018	04/07/2018	
9	17/SC/0602	235629	Behavioural motivation to enhance adherence to oral hygiene recommendations for patients in General Dental Practice	Yes	08/03/2018	01/01/2018	10/01/2018	12/12/2017	05/02/2018	05/02/2018	05/03/2018	
10	17/SC/0616	232772	A Phase IIb, Placebo-Controlled, Dose-Finding Study of Nemralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Severe Exacerbation of COPD	Yes	19/03/2018	27/09/2017	02/02/2018	11/12/2017	07/02/2018	23/02/2018	28/02/2018	
11	17/SC/0631	218932	Optimising wearable technology for remote diagnosis and monitoring of sleep disorders PHASE I ONLY	Yes	22/10/2018	20/11/2017	17/08/2018	30/01/2018	08/08/2018	17/08/2018	16/10/2018	
12	17/WS/0137	228128	A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (VNS-REHAB)	Yes	26/07/2018	05/01/2018	07/06/2018	27/09/2017	07/06/2018	12/06/2018	20/06/2018	

13	17/YH/0097	221010	Home-based Extended Rehabilitation for Older people (HERO): Individually randomised controlled multi-centre trial to determine the clinical and cost effectiveness of a home-based exercise intervention for older people with frailty as extended rehabilitation following acute illness or injury, including embedded process evaluation.	Yes	31/07/2018	27/04/2018	17/05/2018	25/06/2017	31/05/2018	31/05/2018	07/06/2018	
14	17/YH/0388	235066	A multi-center, double-blind, randomized, placebo-controlled study to assess the pharmacodynamics, pharmacokinetics, tolerability, and safety of a single subcutaneous injection of ACT-246475 in adults with stable coronary artery disease	Yes	05/03/2018	26/10/2017	04/01/2018	19/12/2017	16/01/2018	25/01/2018	12/02/2018	
15	17/YH/0394	200610	Clinical Evaluation of Customised Non-Invasive Ventilation interfaces for children (The "COMFORT" study)	Yes	15/10/2018	05/07/2018	12/09/2018	24/08/2018	03/09/2018	13/09/2018	27/09/2018	
16	18/EM/0019	234874	RETurn to work After stroKE: Early vocational rehabilitation compared with usual care for participants: an individually randomised controlled multi-centre pragmatic trial with embedded economic and process evaluations [RETAKE]	Yes	10/07/2018	04/01/2018	01/05/2018	21/02/2018	16/05/2018	24/05/2018	06/06/2018	
17	18/LO/0227	228539	A feasibility study of Acceptance and commitment therapy for people with motor neuron disease (COMMEND)	Yes	25/07/2018	09/03/2018	25/06/2018	13/03/2018	27/06/2018	06/07/2018	09/07/2018	
18	18/LO/0552	242687	Comprehensive Outcomes Registry in Subjects with Epilepsy Treated with Vagus Nerve Stimulation Therapy (CORE VNS)	Yes	19/11/2018	04/04/2018	16/09/2018	29/06/2018	20/08/2018	21/09/2018	28/09/2018	
19	18/NE/0214	245998	A single arm, open label multicentre extension study to evaluate the effectiveness and safety of Ocrelizumab in patients with Multiple Sclerosis previously enrolled in a F. Hoffmann - La Roche sponsored Ocrelizumab Phase IIIb/IV clinical trial	Yes	03/10/2018	19/03/2018	24/09/2018	11/07/2018	24/09/2018	24/09/2018	01/10/2018	
20	18/NW/0008	231939	A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Countries for Dengue	Yes	10/08/2018	13/03/2018	30/07/2018	26/03/2018	31/07/2018	01/08/2018	02/08/2018	
21	18/NW/0236	218224	The AspiRATE study: a proof of concept assessment of a novel intervention to acoustically detect silent aspiration in patients with acquired dysphagia.	Yes	24/05/2018	13/03/2018	08/05/2018	15/05/2018	16/05/2018	16/05/2018	16/05/2018	
22	18/SC/0210	239572	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Evaluate The Efficacy And Safety Of Pf-04965842 Monotherapy In Subjects Aged 12 Years And Older, With Moderate To Severe Atopic Dermatitis	Yes	30/10/2018	06/02/2018	07/09/2018	02/08/2018	29/08/2018	10/09/2018	15/10/2018	

23	16/EM/0380	198726	STUDY 15 – A multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine versus carboplatin/etoposide therapy alone in small cell lung cancer (SCLC)	No		26/03/2018	25/05/2018	09/11/2016	13/07/2018	26/07/2018	09/10/2018	Both
24	16/NE/0140	199321	A randomised placebo-controlled phase III trial of the effect of the omega-3 fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases	No		13/09/2017	30/07/2018	12/01/2018	28/06/2018	13/08/2018	11/09/2018	Neither
25	16/NE/0175	203823	A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy.	No		18/07/2016	11/07/2018	01/12/2016	12/07/2018	02/08/2018		Sponsor
26	16/SS/0014	187949	A double blind placebo controlled trial of a combination of methotrexate and gefitinib versus methotrexate alone as a treatment for ectopic pregnancy	Yes	14/06/2018	03/10/2017	28/03/2018	14/10/2016	12/04/2018	19/04/2018	30/05/2018	Sponsor
27	16/WM/0317	206807	RESTORE-BRAIN: Randomised efficacy and safety trial with oral S44819 after recent ischemic cerebral event. An international, multi-centre, randomized, double-blind, placebo controlled phase II study	Yes	05/10/2018	23/03/2018	04/06/2018	07/10/2016	04/06/2018	07/06/2018	16/06/2018	Neither
28	16/YH/0157	204585	Personalising anal cancer radiotherapy dose – incorporating ACT3, ACT4 and ACT5	Yes	26/06/2018	26/09/2016	29/01/2018	20/07/2016	09/05/2018	23/05/2018	15/06/2018	Neither
29	17/EE/0340	213113	INTERIM: a randomised phase II feasibility study of INTERmittent versus continuous dosing of oral targeted combination therapy In patients with BRAFV600 mutant stage 3 unresectable or metastatic Melanoma	No		02/11/2017	26/03/2018	28/11/2017	26/03/2018	16/05/2018	03/07/2018	NHS Provider
30	17/EE/0382	220851	PROFILE: PRedicting Outcomes For Crohn's disease using a moLecular biomarkEr trial	No		21/12/2017	18/04/2018	02/11/2017	09/04/2018	17/05/2018	12/06/2018	Neither
31	17/EM/0077	206480	LACunar Intervention (LACI-2) Trial-2: Assessment of safety and efficacy of cilostazol and isosorbide mononitrate to prevent recurrent lacunar stroke and progression of cerebral small vessel disease.	Yes	04/10/2018	06/04/2018	29/06/2018	24/07/2017	13/06/2018	06/07/2018	13/09/2018	Sponsor
32	17/ES/0122	230938	Triple therapy prevention of Recurrent Intracerebral Disease Events Trial (TRIDENT)	Yes	04/09/2018	29/01/2018	04/06/2018	03/11/2017	02/07/2018	06/07/2018	21/08/2018	Sponsor
33	17/LO/0169	214075	Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study	No		13/04/2018	13/04/2018	21/04/2017	13/04/2018	20/04/2018	26/04/2018	Sponsor
34	17/LO/0980	219505	HALT: Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours	Yes	25/05/2018	31/10/2017	18/01/2018	10/07/2017	20/03/2018	12/03/2018	29/03/2018	NHS Provider
35	17/LO/1245	208149	A randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis (VITA)	Yes	03/07/2018	21/03/2018	20/04/2018	12/09/2017	27/04/2018	08/05/2018	01/06/2018	Sponsor

36	17/LO/1623	233895	A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of NGM217 in Adults with Autoimmune Diabetes (SAD Study)	Yes	10/12/2018	28/11/2017	10/07/2018	07/11/2017	11/07/2018	17/07/2018	18/09/2018	Neither
37	17/LO/1690	220495	ASTIClite: Autologous Stem cell Transplantation In refractory Crohn's disease - Low Intensity Therapy Evaluation	Yes	14/08/2018	04/12/2017	08/05/2018	15/11/2017	27/04/2018	29/05/2018	11/06/2018	Neither
38	17/NE/0377	233847	A phase 3b, multicentre, prospective, randomized, double blind, placebo-controlled study to reduce incidence of pre-dialysis hyperkalemia with Sodium Zirconium Cyclosilicate (DIALIZE)	No		19/03/2018	04/06/2018	19/02/2018	04/06/2018	07/06/2018	11/06/2018	Neither
39	17/NW/0320	215276	A Phase II Randomised Controlled Study of Oral Prednisolone in Early Diffuse Cutaneous Systemic Sclerosis [PReDSS]	No		22/02/2018	18/04/2018	15/08/2017	11/05/2018	23/05/2018	06/06/2018	Neither
40	17/SS/0082	222441	Start or Stop Anticoagulants Randomised Trial (SoSTART)	Yes	24/04/2018	30/10/2017	02/02/2018	05/10/2017	05/03/2018	20/03/2018	16/04/2018	Sponsor
41	17/WS/0142	221370	PRIMUS 001: A precision PANC clinical study- An adaptive phase 2 study of FOLFOX-A (FOLFOX & nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation	No		19/04/2018	09/07/2018	07/09/2017	16/05/2018	09/07/2018	09/07/2018	Neither
42	17/WS/0147	184216	Precision: Precision-Panc Master Protocol Personalising Treatment for Pancreatic Cancer	No		15/02/2018	14/06/2018	05/01/2018	15/05/2018	09/07/2018	09/07/2018	Neither
43	17/YH/0187	218853	PRISM – A randomised Phase II trial of Nivolumab in combination with alternatively scheduled Ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma	Yes	03/09/2018	18/01/2018	09/07/2018	11/10/2017	31/05/2018	09/07/2018	12/07/2018	Neither
44	17/YH/0390	233236	EFC14867 – A 26-week Randomised, Double-blind, Controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Empagliflozin, and Placebo in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin	No		30/10/2017	18/04/2018	10/01/2018	30/04/2018	02/05/2018	05/06/2018	Sponsor
45	18/EE/0067	242431	Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A [Pathfinder 8]	Yes	12/11/2018	02/05/2018	27/06/2018	06/04/2018	27/06/2018	05/07/2018	04/10/2018	Sponsor
46	18/EE/0153	223791	SALivary electro-stimulation for the treatment of dry mouth in patients with Sjogren's syndrome: a multicentRe randomISEd sham-controlled double-blind study (SALRISE)	Yes	22/10/2018	07/03/2018	05/06/2018	20/07/2018	15/08/2018	22/08/2018	19/09/2018	Sponsor
47	18/EM/0027	235145	A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)	No		23/04/2018	16/07/2018	28/02/2018	21/05/2018	18/07/2018	19/07/2018	Neither

48	18/EM/0113	236887	A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moderate to severe atopic dermatitis [Galapagos]	Yes	28/11/2018	20/03/2018	16/07/2018	09/05/2018	20/08/2018	24/08/2018	17/09/2018	Neither
49	18/LO/0039	232257	Nintedanib as maintenance treatment of malignant pleural mesothelioma (NEMO): a double-blind randomised Phase II study of the EORTC Lung Cancer Group	Yes	16/07/2018	17/07/2017	08/02/2018	05/02/2018	29/03/2018	11/05/2018	12/06/2018	Sponsor
50	18/LO/0144	239494	A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Study to Assess the Safety and Efficacy of Three Doses of Clobetasol Propionate when Administered Intra-orally Twice Daily in Patients with Oral Lichen Planus (OLP) using Rivelin®-CLO Patches	Yes	03/10/2018	25/01/2018	29/06/2018	17/05/2018	19/06/2018	03/07/2018	01/10/2018	Sponsor
51	18/LO/0612	235872	Colchicine and spironolactone in patients with STEMI / synergy stent registry (CLEAR-SYNERGY)	Yes	26/11/2018	03/05/2018	13/08/2018	16/07/2018	13/08/2018	14/08/2018	24/10/2018	Sponsor
52	18/LO/0671	240191	An international, multicentre, open-label, randomised, Phase 3 study of BLU-285 vs Regorafenib in patients with locally advanced unresectable or metastatic Gastrointestinal Stromal Tumour (GIST) - Blueprint	No		23/03/2018	17/07/2018	09/05/2018	18/07/2018	24/07/2018	31/08/2018	Neither
53	18/SC/0139	240580	A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with Advanced c-KIT/PDGFRα Gastrointestinal Stromal TumorS who have Received Prior Treatment with Imatinib, Sunitinib, and/or Regorafenib	Yes	02/08/2018	21/11/2017	25/05/2018	05/05/2018	14/06/2018	27/06/2018	26/07/2018	Sponsor
54	18/SW/0023	238640	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson's Disease [SPARK]	Yes	15/11/2018	26/02/2018	06/09/2018	19/02/2018	29/08/2018	07/09/2018	09/11/2018	Sponsor
55	18/WM/0053	236404	A pilot study of personalised biomarker-base treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck	No		22/03/2018	11/09/2018	17/04/2018	25/05/2018	24/09/2018		Sponsor
56	18/YH/0014	224065	External frame versus internal locking plate for articular pilon fracture fixation in adult patients -a multi-centre randomised controlled trial [ACTIVE]	No		29/03/2018	20/06/2018	13/02/2018	08/06/2018	27/06/2018	05/07/2018	Neither
57	18/YH/0069	242258	A Randomized, Open-label Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [GLOW]	Yes	16/10/2018	06/02/2018	24/07/2018	04/06/2018	11/07/2018	24/07/2018	24/07/2018	Neither
58	18/YH/0108	233888	Prolonged enoxaparin in primary percutaneous coronary intervention compared with standard of care therapy -The PENNYWISE feasibility study	Yes	23/08/2018	21/02/2018	13/06/2018	05/06/2018	28/06/2018	28/06/2018	28/06/2018	Neither